Skip to content
AusperBio
-
AusperBio raises US$120M to advance Hepatitis B therapies toward functional cure
AusperBio will use a significant portion of the proceeds to advance AHB 137, an antisense oligonucleotide therapy for CHB, through its Phase III registrational programme and toward potential commercialisation.
-
AusperBio begins patient dosing in trial of Hepatitis B siRNA candidate AHB-171
The latest milestone advances the company’s second clinical-stage therapeutic candidate and marks the first clinical programme built using its proprietary Au-HALO™ liver-targeting delivery technology and siRNA platform.